Screener
Kestra Medical Technologies KMTS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Kestra Medical Technologies in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Kestra Medical Technologies’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 5:16 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001193125-26-303397
| Line item | April 30, 2026 | April 30, 2025 |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $99,710 | $237,595 |
| Short-term investments | 96,724 | — |
| Accounts receivable, net | 14,542 | 8,081 |
| Disposable medical equipment supplies | 6,706 | 6,572 |
| Prepaid expenses and other current assets | 4,677 | 3,080 |
| Total current assets | 222,359 | 255,328 |
Item 16. Form 10-K Summary.
FAQ
- What is Kestra Medical Technologies's cash & equivalents?
- Kestra Medical Technologies (KMTS) reported cash & equivalents of $99.71M in Q1 2026.
- How has Kestra Medical Technologies's cash & equivalents changed year-over-year?
- Kestra Medical Technologies's cash & equivalents decreased by 58.0% year-over-year, from $237.6M to $99.71M.
- What is the long-term trend for Kestra Medical Technologies's cash & equivalents?
- Over 2 years (2024 to 2026), Kestra Medical Technologies's cash & equivalents has grown at a 247.7% compound annual growth rate (CAGR), from $8.25M to $99.71M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Kestra Medical Technologies's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude